Abstract
Cancer nanotherapeutics have shown promise in resolving some of the limitations of conventional drug delivery systems such as nonspecific biodistribution and targeting, lack of water solubility, low therapeutic indices, and poor oral bioavailability. Moreover, cancer nanotechnology has the potential of improving current approaches to cancer detection, diagnosis, and imaging. Recently, nanotechnology and molecular imaging have been combined to generate nanoparticles that simultaneously facilitate cancer therapy and diagnosis, the so called theragnostic nanoparticles. The aim of our review is to highlight recent developments within the context of the current knowledge of nanotechnology, to recall the experimental steps that have brought to the clinical development and application of nanoparticles, and explain the biological rationale for their use with oncologic patients. In particular, we summarize recent findings with respect to possible new applications for therapy and diagnosis, and their specific properties. Moreover, we report the more recent prospects in gene therapy, the possibility of using new drug delivery methods, the action of nanoparticles on the immune system and apoptosis, and the concrete possibility of detecting and characterizing circulating tumor cells or of developing new technologies in drug discovery.
Keywords: Drug delivery, gene therapy, imaging, nanoparticles, nanovectors, nanotechnology, theragnostic molecules, chitosan-based nanoparticles (CNPs), polyethylene glycol PEG, Docetaxel, Magnetic drug targeting (MDT)
Anti-Cancer Agents in Medicinal Chemistry
Title: Nanoparticles in Oncology: The New Theragnostic Molecules
Volume: 11 Issue: 7
Author(s): Alessandro Allegra, Giuseppa Penna, Andrea Alonci, Vincenzo Rizzo, Sabina Russo and Caterina Musolino
Affiliation:
Keywords: Drug delivery, gene therapy, imaging, nanoparticles, nanovectors, nanotechnology, theragnostic molecules, chitosan-based nanoparticles (CNPs), polyethylene glycol PEG, Docetaxel, Magnetic drug targeting (MDT)
Abstract: Cancer nanotherapeutics have shown promise in resolving some of the limitations of conventional drug delivery systems such as nonspecific biodistribution and targeting, lack of water solubility, low therapeutic indices, and poor oral bioavailability. Moreover, cancer nanotechnology has the potential of improving current approaches to cancer detection, diagnosis, and imaging. Recently, nanotechnology and molecular imaging have been combined to generate nanoparticles that simultaneously facilitate cancer therapy and diagnosis, the so called theragnostic nanoparticles. The aim of our review is to highlight recent developments within the context of the current knowledge of nanotechnology, to recall the experimental steps that have brought to the clinical development and application of nanoparticles, and explain the biological rationale for their use with oncologic patients. In particular, we summarize recent findings with respect to possible new applications for therapy and diagnosis, and their specific properties. Moreover, we report the more recent prospects in gene therapy, the possibility of using new drug delivery methods, the action of nanoparticles on the immune system and apoptosis, and the concrete possibility of detecting and characterizing circulating tumor cells or of developing new technologies in drug discovery.
Export Options
About this article
Cite this article as:
Allegra Alessandro, Penna Giuseppa, Alonci Andrea, Rizzo Vincenzo, Russo Sabina and Musolino Caterina, Nanoparticles in Oncology: The New Theragnostic Molecules, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (7) . https://dx.doi.org/10.2174/187152011796817682
DOI https://dx.doi.org/10.2174/187152011796817682 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progress in Gene Delivery by Cationic Lipids : Guanidinium-Cholesterol-Based Systems as an Example
Current Drug Targets Consumer Understanding and Use of Health Claims: The Case of Functional Foods
Recent Patents on Food, Nutrition & Agriculture Molecular Target-Guided Tumor Therapy with Natural Products Derived from Traditional Chinese Medicine
Current Medicinal Chemistry It’s Time to Talk: Challenges in Providing Integrated Palliative Care in Advanced Congestive Heart Failure. A Narrative Review
Current Cardiology Reviews Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer
Current Stem Cell Research & Therapy PUFA for Prevention and Treatment of Dementia?
Current Pharmaceutical Design Synthesis and Biological Evaluation of Some Hydrazone Derivatives as Anti-inflammatory Agents
Letters in Drug Design & Discovery Novel Artemisinin-Derived Dimers: Synthesis and Evaluation of Anti-cancer Activities
Letters in Drug Design & Discovery Is Elevated Norepinephrine an Etiological Factor in Some Cases of Alzheimers Disease?
Current Alzheimer Research Synthesis and In Vitro Anticancer Activity of 6-Ferrocenylpyrimidin-4(3H)-one Derivatives
Current Organic Synthesis Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors
Current Drug Targets An Implantable Drug-delivery System on a Chip
Current Topics in Medicinal Chemistry Developing New Anti-Arrhythmics: Clues from the Molecular Basis of Cardiac Ryanodine Receptor (RyR2) Ca2+-Release Channel Dysfunction
Current Pharmaceutical Design Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities
Current Pharmaceutical Biotechnology Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections
Current Pharmaceutical Design Anti-angiogenic Therapy and Induction of Blood Vessel Normalization in the Treatment of Ovarian Cancer
Current Angiogenesis (Discontinued) The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Viral Product Trafficking to Mitochondria, Mechanisms and Roles in Pathogenesis
Infectious Disorders - Drug Targets Synthesis and In Vitro Anti-Lung Cancer Activity of Novel 1, 3, 4, 8- Tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-o ne Alkaloid Analogs
Medicinal Chemistry